{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:14:09Z","timestamp":1790162049680,"version":"4.1.0"},"reference-count":80,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Castleman disease (CD) comprises a heterogenous group of rare nonmalignant lymphoproliferative disorders. CD is classified as unicentric (UCD) and multicentric CD (MCD) depending on the number of lymph node region involvement. Oligocentric CD (OligoCD) is a recently validated provisional subtype with intermediate clinical features and outcomes. MCD is further subcategorized by etiology into three distinct entities: (1) human herpesvirus 8 (HHV\u20108) associated (HHV\u20108+) MCD, (2) idiopathic MCD (iMCD), (3) polyneuropathy, organomegaly, endocrinopathy, monoclonal proteins, and skin changes (POEMS)\u2010associated MCD. Idiopathic MCD itself encompasses three clinical subtypes: iMCD\u2010TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis\/renal dysfunction, and organomegaly), idiopathic plasmacytic lymphadenopathy (iMCD\u2010IPL), and iMCD\u2010NOS (not otherwise specified). Recent advances suggest that CD comprises biologically distinct entities with unique genetic landscapes, cellular origins, and mechanisms underlying interleukin\u20106 production. MCD is thought to arise from multifactorial mechanisms, including autoimmune dysregulation, chronic inflammatory processes, and paraneoplastic phenomena. The diagnosis of CD remains challenging due to its overlapping features with a broad range of reactive and malignant disorders, as well as its potential coexistence with other underlying conditions. This review focuses on the cell origins and biological mechanisms underlying CD, with particular emphasis on distinguishing CD from conditions with overlapping features, thereby enhancing our understanding of its pathogenesis and disease biology.<\/jats:p>","DOI":"10.1111\/ejh.70298","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:45:48Z","timestamp":1790160348000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Castleman Disease: Unraveling Diagnostic Challenges Through Clinical and Pathologic Perspectives"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-3971","authenticated-orcid":false,"given":"Aditi","family":"Saha","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-1458","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Laboratory Medicine H. Lee Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"1","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman Disease","volume":"7","author":"Carbone A.","year":"2021","journal-title":"Nature Reviews. Disease Primers"},{"issue":"12","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and Pathological Characteristics of HIV\u2010 and HHV\u20108\u2013Negative Castleman Disease","volume":"129","author":"Yu L.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_4_1","article-title":"Expert Perspective: Diagnosis and Treatment of Castleman Disease. Arthritis","author":"Chen L. Y. C.","year":"2026","journal-title":"Rheumatologist"},{"issue":"8","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/bloodadvances.2024014391","article-title":"Characterizing the Heterogeneity of Castleman Disease and Oligocentric Subtype: Findings From the ACCELERATE Registry","volume":"9","author":"Pierson S. K.","year":"2025","journal-title":"Blood Advances"},{"issue":"3","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2017.11.005","article-title":"Clinical, Laboratory and Imaging Findings in Castleman's Disease\u2014The Subtype Decides","volume":"32","author":"Haap M.","year":"2018","journal-title":"Blood Reviews"},{"issue":"19","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV\u20108\u2010Negative, Idiopathic Multicentric Castleman Disease: Novel Insights Into Biology, Pathogenesis, and Therapy","volume":"123","author":"Fajgenbaum D. C.","year":"2014","journal-title":"Blood"},{"issue":"16","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman Disease","volume":"135","author":"Dispenzieri A.","year":"2020","journal-title":"Blood"},{"issue":"12","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, Evidence\u2010Based Consensus Diagnostic Criteria for HHV\u20108\u2013Negative\/Idiopathic Multicentric Castleman Disease","volume":"129","author":"Fajgenbaum D. C.","year":"2017","journal-title":"Blood"},{"issue":"18","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2023021992","article-title":"Single\u2010Cell Landscape of Idiopathic Multicentric Castleman Disease in Identical Twins","volume":"143","author":"Chan J. Y.","year":"2024","journal-title":"Blood"},{"issue":"2","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00428-025-04171-w","article-title":"The Morphological Spectrum of Castleman Disease and Related Disorders: A Report From the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology","volume":"487","author":"Gasljevic G.","year":"2025","journal-title":"Virchows Archiv"},{"issue":"22","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel Insights and Therapeutic Approaches in Idiopathic Multicentric Castleman Disease","volume":"132","author":"Fajgenbaum D. C.","year":"2018","journal-title":"Blood"},{"issue":"23","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International Evidence\u2010Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease","volume":"4","author":"Rhee F.","year":"2020","journal-title":"Blood Advances"},{"issue":"4","key":"e_1_2_11_14_1","article-title":"A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease","volume":"10","author":"Butzmann A.","year":"2021","journal-title":"Biology (Basel)"},{"issue":"4","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB Mutations in Unicentric Castleman Disease","volume":"33","author":"Li Z.","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next\u2010Generation Sequencing of Idiopathic Multicentric and Unicentric Castleman Disease and Follicular Dendritic Cell Sarcomas","volume":"2","author":"Nagy A.","year":"2018","journal-title":"Blood Advances"},{"issue":"4","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV\u20108 Is Associated With a Plasmablastic Variant of Castleman Disease That Is Linked to HHV\u20108\u2013Positive Plasmablastic Lymphoma","volume":"95","author":"Dupin N.","year":"2000","journal-title":"Blood"},{"issue":"7","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood.V97.7.2130","article-title":"Kaposi Sarcoma\u2010Associated Herpesvirus Infects Monotypic (IgM Lambda) but Polyclonal Naive B Cells in Castleman Disease and Associated Lymphoproliferative Disorders","volume":"97","author":"Du M. Q.","year":"2001","journal-title":"Blood"},{"issue":"5","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328355e0f3","article-title":"Recent Advances in Kaposi Sarcoma Herpesvirus\u2010Associated Multicentric Castleman Disease","volume":"24","author":"Uldrick T. S.","year":"2012","journal-title":"Current Opinion in Oncology"},{"issue":"5","key":"e_1_2_11_20_1","first-page":"e64","article-title":"Whole\u2010Exome Sequencing Identifies Novel Somatic Alterations Associated With Outcomes in Idiopathic Multicentric Castleman Disease","volume":"188","author":"You L.","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"5","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/jamadermatol.2016.5554","article-title":"JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease","volume":"153","author":"Patel M.","year":"2017","journal-title":"JAMA Dermatology"},{"issue":"6","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/ejh.13702","article-title":"Novel Somatic Alterations in Unicentric and Idiopathic Multicentric Castleman Disease","volume":"107","author":"Goodman A. M.","year":"2021","journal-title":"European Journal of Haematology"},{"issue":"1","key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1038\/s41467-025-61214-1","article-title":"Spatial and Single Cell Mapping of Castleman Disease Reveals Key Stromal Cell Types and Cytokine Pathways","volume":"16","author":"Smith D.","year":"2025","journal-title":"Nature Communications"},{"issue":"15","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1038\/s41388-020-1204-9","article-title":"Genetic Basis for iMCD\u2010TAFRO","volume":"39","author":"Yoshimi A.","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/keaa269","article-title":"Idiopathic Multicentric Castleman Disease With Novel Heterozygous Ile729Met Mutation in Exon 10 of Familial Mediterranean Fever Gene","volume":"60","author":"Endo Y.","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"e_1_2_11_26_1","first-page":"1705","article-title":"Distinct Interleukin\u20106 Production in IPL and TAFRO Subtypes of Idiopathic Multicentric Castleman Disease","volume":"111","author":"Nishikori A.","year":"2026","journal-title":"Haematologica"},{"issue":"9","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/ajh.27743","article-title":"International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis","volume":"100","author":"Nishimura M. F.","year":"2025","journal-title":"American Journal of Hematology"},{"issue":"1","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1038\/s41467-022-34873-7","article-title":"CXCL13 Is a Predictive Biomarker in Idiopathic Multicentric Castleman Disease","volume":"13","author":"Pierson S. K.","year":"2022","journal-title":"Nature Communications"},{"issue":"11","key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"E334","DOI":"10.1002\/ajh.27065","article-title":"Ongoing Symptoms Following Complete Surgical Excision in Unicentric Castleman Disease","volume":"98","author":"Sarmiento Bustamante M.","year":"2023","journal-title":"American Journal of Hematology"},{"issue":"6","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/bjh.70480","article-title":"Deciphering the Full Spectrum of Castleman Diseases Based on a Cohort of 700 Patients in a Western Country","volume":"208","author":"Oksenhendler E.","year":"2026","journal-title":"British Journal of Haematology"},{"issue":"3","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/aqaf147","article-title":"How I Diagnose Castleman Disease","volume":"165","author":"Laczko D.","year":"2026","journal-title":"American Journal of Clinical Pathology"},{"issue":"1","key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi Sarcoma Herpesvirus\u2013Associated Multicentric Castleman Disease","volume":"32","author":"Lurain K.","year":"2018","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"e_1_2_11_33_1","unstructured":"C.DavidandM.Fajgenbaum \u201cMBA MSc. Castleman Disease. UptoDate\u201d(2024)."},{"issue":"2","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.19171","article-title":"The Application of a Multidisciplinary Approach in the Diagnosis of Castleman Disease and Castleman\u2010Like Lymphadenopathies: A 20\u2010Year Retrospective Analysis of Clinical and Pathological Features","volume":"204","author":"Pelliccia S.","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"11","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.6004\/jnccn.2019.5037","article-title":"Diagnosis and Management of Castleman Disease","volume":"17","author":"Abramson J. S.","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman Disease","volume":"32","author":"Wu D.","year":"2018","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"7","key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R.","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/00000478-199711000-00004","article-title":"Angiomyoid and Follicular Dendritic Cell Proliferative Lesions in Castleman's Disease of Hyaline Clinicopathologic Features and Outcomes of Follicular Dendritic Cell Sarcoma With or Without Castleman Disease Vascular Type: A Study of 10 Cases","volume":"21","author":"Lin O.","year":"1997","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2559.1991.tb01500.x","article-title":"Expression of ICAM\u20101, VCAM\u20101 and ELAM\u20101 in Angiofollicular Lymph Node Hyperplasia (Castleman's Disease): Evidence for Dysplasia of Follicular Dendritic Reticulum Cells","volume":"19","author":"Ruco L. P.","year":"1991","journal-title":"Histopathology"},{"issue":"1","key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5858\/arpa.2022-0404-RA","article-title":"Unicentric Castleman Disease: Illustration of Its Morphologic Spectrum and Review of the Differential Diagnosis","volume":"148","author":"El Hussein S.","year":"2023","journal-title":"Archives of Pathology & Laboratory Medicine"},{"issue":"16","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"11549","DOI":"10.1200\/JCO.2025.43.16_suppl.11549","article-title":"Clinicopathologic Features and Outcomes of Follicular Dendritic Cell Sarcoma With or Without Castleman Disease: A Large Retrospective Cohort Analysis","volume":"43","author":"Nishimura Y.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.32074\/1591-951X-331","article-title":"Follicular Dendritic Cell Sarcoma","volume":"113","author":"Facchetti F.","year":"2021","journal-title":"Pathologica"},{"issue":"2","key":"e_1_2_11_43_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.critrevonc.2013.05.006","article-title":"Dendritic Cell Sarcoma: A Pooled Analysis Including 462 Cases With Presentation of Our Case Series","volume":"88","author":"Saygin C.","year":"2013","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"e_1_2_11_44_1","first-page":"144","article-title":"Follicular Dendritic Cell Tumor: Review of the Entity","volume":"15","author":"Perez\u2010Ordo\u00f1ez B.","year":"1998","journal-title":"Seminars in Diagnostic Pathology"},{"issue":"6","key":"e_1_2_11_45_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/modpathol.2013.202","article-title":"Monoclonality and Cytogenetic Abnormalities in Hyaline Vascular Castleman Disease","volume":"27","author":"Chang K. C.","year":"2014","journal-title":"Modern Pathology"},{"issue":"6","key":"e_1_2_11_46_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/00000478-200006000-00016","article-title":"A Chromosomal Abnormality in Hyaline Vascular Castleman's Disease: Evidence for Clonal Proliferation of Dysplastic Stromal Cells","volume":"24","author":"Pauwels P.","year":"2000","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"e_1_2_11_47_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1365-2559.2001.01134.x","article-title":"Development of Follicular Dendritic Cell Sarcoma in Hyaline\u2013Vascular Castleman's Disease of the Nasopharynx: Tracing Its Evolution by Sequential Biopsies","volume":"38","author":"Chan A. C.","year":"2001","journal-title":"Histopathology"},{"key":"e_1_2_11_48_1","doi-asserted-by":"crossref","first-page":"1637792","DOI":"10.3389\/fimmu.2025.1637792","article-title":"Oligocentric Castleman Disease: Clinical Characteristics and Surgical Outcomes From a Single\u2010Centre Retrospective Study","volume":"16","author":"Duan Y.","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"e_1_2_11_49_1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/bloodadvances.2025018324","article-title":"Comprehensive Analysis of Subtype\u2010Specific Outcomes and Management in Castleman Disease: A 20\u2010Year Cohort Study","volume":"10","author":"Nishimura Y.","year":"2026","journal-title":"Blood Advances"},{"issue":"5","key":"e_1_2_11_50_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/QAD.0000000000004094","article-title":"Haemophagocytic Lymphohistiocytosis in HIV\u2010Associated HHV\u20108\u2013Positive Multicentric Castleman Disease","volume":"39","author":"Migaud P.","year":"2025","journal-title":"AIDS"},{"issue":"6","key":"e_1_2_11_51_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/cid\/cis1009","article-title":"Human Herpesvirus 8\u2013Related Castleman Disease in the Absence of HIV Infection","volume":"56","author":"Dossier A.","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"e_1_2_11_52_1","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/rheumatology\/keac481","article-title":"Idiopathic Multicentric Castleman Disease and Associated Autoimmune and Autoinflammatory Conditions: Practical Guidance for Diagnosis","volume":"62","author":"Gonz\u00e1lez Garc\u00eda A.","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10","key":"e_1_2_11_53_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated International Definition of the Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly Clinical Subtype (TAFRO) of Idiopathic Multicentric Castleman Disease","volume":"96","author":"Nishimura Y.","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"4","key":"e_1_2_11_54_1","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic Multicentric Castleman's Disease: A Systematic Literature Review","volume":"3","author":"Liu A. Y.","year":"2016","journal-title":"Lancet Haematology"},{"issue":"7","key":"e_1_2_11_55_1","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00432-020-03494-2","article-title":"Clinical Characteristics and Immunological Abnormalities of Castleman Disease Complicated With Autoimmune Diseases","volume":"147","author":"Sun D. P.","year":"2021","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"e_1_2_11_56_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1440-1827.2000.01052.x","article-title":"Reactive Follicular Hyperplasia in the Lymph Node Lesions From Systemic Lupus Erythematosus Patients: A Clinicopathological and Immunohistological Study of 21 Cases","volume":"50","author":"Kojima M.","year":"2000","journal-title":"Pathology International"},{"issue":"6","key":"e_1_2_11_57_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.prp.2007.03.002","article-title":"Histological Diversity of Reactive and Atypical Proliferative Lymph Node Lesions in Systemic Lupus Erythematosus Patients","volume":"203","author":"Kojima M.","year":"2007","journal-title":"Pathology, Research and Practice"},{"issue":"1","key":"e_1_2_11_58_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41379-019-0365-y","article-title":"KSHV\/HHV8\u2010Positive Large B\u2010Cell Lymphomas and Associated Diseases: A Heterogeneous Group of Lymphoproliferative Processes With Significant Clinicopathological Overlap","volume":"33","author":"Vega F.","year":"2020","journal-title":"Modern Pathology"},{"issue":"1","key":"e_1_2_11_59_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jcp-2023-209280","article-title":"Diagnostic Challenges of the Idiopathic Plasmacytic Lymphadenopathy (IPL) Subtype of Idiopathic Multicentric Castleman Disease (iMCD): Factors to Differentiate From IgG4\u2010Related Disease","volume":"79","author":"Nishikori A.","year":"2025","journal-title":"Journal of Clinical Pathology"},{"issue":"4","key":"e_1_2_11_60_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/modpathol.2009.17","article-title":"Systemic IgG4\u2010Related Lymphadenopathy: A Clinical and Pathologic Comparison to Multicentric Castleman's Disease","volume":"22","author":"Sato Y.","year":"2009","journal-title":"Modern Pathology"},{"issue":"7","key":"e_1_2_11_61_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/pin.12932","article-title":"Clinicopathological Differential Diagnosis of IgG4\u2010Related Disease: A Historical Overview and a Proposal of the Criteria for Excluding Mimickers of IgG4\u2010Related Disease","volume":"70","author":"Satou A.","year":"2020","journal-title":"Pathology International"},{"issue":"2","key":"e_1_2_11_62_1","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/RHU.0000000000001787","article-title":"IgG4\u2010Related Disease: Mimickers and Diagnostic Pitfalls","volume":"28","author":"Mart\u00edn\u2010Nares E.","year":"2022","journal-title":"Journal of Clinical Rheumatology"},{"issue":"2","key":"e_1_2_11_63_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","article-title":"Immunoglobulin G4\u2010Related Disease and Idiopathic Multicentric Castleman's Disease: Confusable Immune\u2010Mediated Disorders","volume":"61","author":"Sasaki T.","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"e_1_2_11_64_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.32074\/1591-951X-351","article-title":"Multicentric Castleman Disease and the Evolution of the Concept","volume":"113","author":"Zhou T.","year":"2021","journal-title":"Pathologica"},{"issue":"1","key":"e_1_2_11_65_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pin.13185","article-title":"Investigation of IgG4\u2010Positive Cells in Idiopathic Multicentric Castleman Disease and Validation of the 2020 Exclusion Criteria for IgG4\u2010Related Disease","volume":"72","author":"Nishikori A.","year":"2022","journal-title":"Pathology International"},{"issue":"9","key":"e_1_2_11_66_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus Statement on the Pathology of IgG4\u2010Related Disease","volume":"25","author":"Deshpande V.","year":"2012","journal-title":"Modern Pathology"},{"issue":"7","key":"e_1_2_11_67_1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.25495","article-title":"POEMS Syndrome: 2019 Update on Diagnosis, Risk\u2010Stratification, and Management","volume":"94","author":"Dispenzieri A.","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"2","key":"e_1_2_11_68_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic Analysis of TAFRO Syndrome Demonstrates a Distinct Subtype of HHV\u20108\u2013Negative Multicentric Castleman Disease","volume":"91","author":"Iwaki N.","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"1","key":"e_1_2_11_69_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 Updated Diagnostic Criteria and Disease Severity Classification for TAFRO Syndrome","volume":"111","author":"Masaki Y.","year":"2020","journal-title":"International Journal of Hematology"},{"issue":"3","key":"e_1_2_11_70_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman Disease and TAFRO Syndrome","volume":"101","author":"Masaki Y.","year":"2022","journal-title":"Annals of Hematology"},{"issue":"6","key":"e_1_2_11_71_1","article-title":"Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease\/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome","volume":"12","author":"Sumiyoshi R.","year":"2024","journal-title":"Biomedicine"},{"issue":"5","key":"e_1_2_11_72_1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17993","article-title":"Glycogen Synthase Kinase 3\u03b2\/CCR6\u2010Positive Bone Marrow Cells Correlate With Disease Activity in Multicentric Castleman Disease\u2010TAFRO","volume":"196","author":"Abe N.","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"23","key":"e_1_2_11_73_1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum D. C.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"e_1_2_11_74_1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO Syndrome a Subtype of Idiopathic Multicentric Castleman Disease?","volume":"94","author":"Fujimoto S.","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"5","key":"e_1_2_11_75_1","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic Multicentric Castleman Disease (iMCD)\u2010Idiopathic Plasmacytic Lymphadenopathy: A Distinct Subtype of iMCD\u2010Not Otherwise Specified With Different Clinical Features and Better Survival","volume":"204","author":"Gao Y.\u2010h.","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"18","key":"e_1_2_11_76_1","doi-asserted-by":"crossref","first-page":"10301","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease","volume":"23","author":"Nishikori A.","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"e_1_2_11_77_1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)\u2010Associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS)","volume":"62","author":"Polizzotto M. N.","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"22","key":"e_1_2_11_78_1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/bloodadvances.2025016685","article-title":"Characteristics and Outcomes of Kaposi Sarcoma Herpesvirus\u2013Associated Inflammatory Cytokine Syndrome","volume":"9","author":"Ramaswami R.","year":"2025","journal-title":"Blood Advances"},{"issue":"4","key":"e_1_2_11_79_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.18518","article-title":"A Novel Approach for Characterization of KSHV\u2010Associated Multicentric Castleman Disease From Effusions","volume":"200","author":"Zhou T.","year":"2023","journal-title":"British Journal of Haematology"},{"issue":"24","key":"e_1_2_11_80_1","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1182\/bloodadvances.2025018106","article-title":"Time to Redefine HHV\u20108 MCD and KICS Criteria?","volume":"9","author":"Stammler R.","year":"2025","journal-title":"Blood Advances"},{"issue":"3","key":"e_1_2_11_81_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bjh.17688","article-title":"The Management of Castleman Disease","volume":"195","author":"Lomas O. C.","year":"2021","journal-title":"British Journal of Haematology"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:46:00Z","timestamp":1790160360000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":80,"alternative-id":["10.1111\/ejh.70298"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70298","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70298"}}